Nevertheless, data are consistent with previous findings showing improvement in body composition, glycemic parameters and insulin sensitivity following treatment with UAG or AZP-531 in obesity and diabetes conditions in animals and humans and suggest that AZP-531 reproduces these effects on adipose tissue and insulin sensitivity in patients with PWS. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.